See more : XTL Biopharmaceuticals Ltd. (XTLB) Income Statement Analysis – Financial Results
Complete financial analysis of Hepion Pharmaceuticals, Inc. (HEPA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hepion Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Maxcom S.A. (MXC.WA) Income Statement Analysis – Financial Results
- VinFast Auto Ltd. (VFSWW) Income Statement Analysis – Financial Results
- Indian Energy Exchange Limited (IEX.NS) Income Statement Analysis – Financial Results
- Permanent Technologies, Inc. (PERT) Income Statement Analysis – Financial Results
- Zenith Energy Ltd. (ZEN.L) Income Statement Analysis – Financial Results
Hepion Pharmaceuticals, Inc. (HEPA)
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 0.00 | 21.53K | 16.36K | 0.00 | 0.00 |
| Gross Profit | -67.13K | -77.46K | -86.07K | -34.52K | -26.74K | -18.79K | -21.94K | 0.00 | -21.53K | -16.36K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 35.64M | 33.27M | 20.40M | 12.00M | 3.18M | 7.59M | 14.33M | 13.65M | 15.02M | 8.40M | 314.25K | 734.56K |
| General & Administrative | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 7.28M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -583.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 6.69M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Other Expenses | 3.19M | 0.00 | 0.00 | 0.00 | -179.65K | -108.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.02M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Cost & Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.04M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.47K | 10.16K | 8.86K | 31.23K | 555.00K | 339.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 27.99K | 21.53K | 16.36K | 1.32K | 841.00K |
| EBITDA | -49.26M | -43.54M | -30.32M | -20.11M | -7.74M | -14.58M | -20.62M | -21.02M | -20.81M | -13.94M | -1.67M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.45M | -45.49M | -30.40M | -20.15M | -7.77M | -14.59M | -21.04M | -21.02M | -20.81M | -13.96M | -1.67M | -841.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -887.11K | 404.83K | -2.32M | -177.28K | -175.94K | 4.61M | 2.13M | 4.22M | 3.81M | -387.90K | -3.61M | -1.97K |
| Income Before Tax | -49.34M | -45.08M | -32.72M | -20.32M | -7.95M | -9.99M | -18.92M | -16.80M | -17.00M | -14.35M | -5.28M | -842.97K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -409.02K | -2.88M | 8.86K | 30.58K | -908.68K | -536.00K | -3.90M | -1.91M | -3.81M | 387.90K | 3.61M | -1.97K |
| Net Income | -48.93M | -42.20M | -32.72M | -20.35M | -7.04M | -9.45M | -15.02M | -14.89M | -17.00M | -14.35M | -5.28M | -842.97K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| EPS Diluted | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| Weighted Avg Shares Out | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.20K | 2.42K | 1.94K | 1.14K | 33.00K |
| Weighted Avg Shares Out (Dil) | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.21K | 2.42K | 1.94K | 1.14K | 33.00K |
XBI: The Worst Is Over
Hepion Pharmaceuticals: Facing The Momentous Year 2022
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
HEPA Stock: Why It Increased Today
All Endpoints Met in Hepion Pharmaceuticals' Drug-Drug Interaction Study with CRV431
Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Hepion Pharma Shares Encouraging Biomarker Data From NASH Trial
HEPA Stock: Why It Increased Today
Why Are Hepion Pharma Shares Moving Higher Premarket Monday?
Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION' Clinical Trial of CRV431 in NASH
Source: https://incomestatements.info
Category: Stock Reports